Related Experiment Video
Updated: Feb 23, 2026
Isolation of Soluble and Insoluble PrP Oligomers in the Normal Human Brain
Published on: October 3, 2012
Molecular Subtyping of PrPres in Human Sporadic CJD Brain Tissue
G M Klug1, V Lewis1, S J Collins2
1Department of Medicine, Royal Melbourne Hospital, The University of Melbourne, Parkville, VIC, 3010, Australia.
Abstract:
Across the spectrum of sporadic human prion diseases (also known as transmissible spongiform encephalopathies: TSE), there is considerable phenotypic diversity. Cumulative scientific evidence supports that prions, the infectious agents of prion diseases, are constituted predominantly, if not exclusively, by misfolded, typically protease-resistant, disease-associated isoforms of the prion protein (PrPres). Consequently, tissue deposition of PrPres is considered a hallmark of prion disease pathology, and this can be visualized by Western blotting after tissue homogenization and treatment with proteinases, particularly proteinase K (PK). Indeed, Western blot profiles of PrPres are utilized as one marker of different prion strains, with such strains thought to contribute to at least part of the phenotypic variation observed in sporadic human prion disease. Typically, Western blotting of PrPres demonstrates three bands of different electrophoretic mobility, depicting the di-glycosylated, mono-glycosylated and unglycosylated species although further subclassification and the delineation of novel sporadic disease subtypes, such as variably protease-sensitive prionopathy, has contributed greater complexity. Nevertheless, it is the mobility of the unglycosylated PrPres band, the relative abundance of the two glycosylated bands or overall profile of the banding post-PK, in combination with the prion protein gene (PRNP) codon 129 genotype that allows the categorisation of molecular subtypes of sporadic human prion disease. These subtypes appear to correlate with distinct clinico-pathological profiles of sporadic Creutzfeldt-Jakob disease.
Insights
Prion diseases, or transmissible spongiform encephalopathies, show diverse symptoms. Prion protein (PrP) characteristics, analyzed by Western blotting, help classify subtypes of these rare brain diseases.
Area of Science:
- Neurology
- Biochemistry
- Molecular Biology
Background:
- Sporadic human prion diseases, also known as transmissible spongiform encephalopathies (TSE), exhibit significant phenotypic diversity.
- Prions, the infectious agents, are primarily misfolded prion proteins (PrPres), a hallmark of disease pathology.
- PrPres deposition in tissues is visualized via Western blotting after proteinase K (PK) treatment.
Purpose of the Study:
- To explore the relationship between PrPres characteristics and the phenotypic diversity in sporadic human prion diseases.
- To investigate how Western blot profiles of PrPres contribute to classifying prion disease subtypes.
- To understand the correlation between molecular subtypes and clinico-pathological profiles.
Main Methods:
- Western blotting of PrPres after tissue homogenization and proteinase K digestion.
- Analysis of PrPres banding patterns, including glycosylated and unglycosylated species.
- Correlation of PrPres profiles with the prion protein gene (PRNP) codon 129 genotype.
Main Results:
- Western blot profiles of PrPres, particularly the unglycosylated band mobility and glycosylation patterns, serve as markers for different prion strains.
- Subclassification of PrPres profiles, including novel subtypes like variably protease-sensitive prionopathy, adds complexity.
- PrPres banding patterns, combined with PRNP codon 129 genotype, enable the categorization of sporadic human prion disease molecular subtypes.
Conclusions:
- Molecular subtypes of sporadic human prion disease, defined by PrPres profiles and PRNP genotype, correlate with distinct clinico-pathological presentations.
- Western blot analysis of PrPres is crucial for understanding prion disease heterogeneity.
- Further subclassification aids in characterizing rare prion diseases and their associated clinical outcomes.
